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The rise of drug-resistant tuberculosis threatens the very fab-
ric of traditional tuberculosis control efforts, particularly in South
Africa, Eastern Europe and parts of Asia. Initial complacency
was guided by laboratory observations which suggested that
drug-resistant strains of Mycobacterium tuberculosis are less trans-
missible than drug-susceptible “wild-type” strains.
However, the fact that young children in close contactwith adult
drug-resistant tuberculosis patients frequently became infected
and/or diseased, usually with the same strain, provided clear evi-
dence of transmissibility. Advanced genomic analysis has since
provided novel insight into the evolution and spread of drug-
resistant strains, highlighting unique epidemiological features
related to programmatic management in speciﬁc geographic areas.
Young children and immune compromised individuals are at
high risk todevelopactive tuberculosis following close contactwith
a drug-resistant source case. Although observational data demon-
strate clearbeneﬁt fromcontextualizedpost-exposureprophylaxis,
formal guidance remains limited pendingmore robust information
from large ﬁeld trials.
Wide scale roll-out of the MTB/RIF Xpert® test has facilitated
early diagnosis of cases with drug-resistant tuberculosis. Multiple
challenges such as high cost, technical and maintenance issues,
result interpretation, false positive read-outs and misassignment
of multi-drug resistant (MDR) status in cases with rifampicin
mono-resistance remain, especially in resource-limited settings.
In addition, MDR treatment programs are inadequate and heavily
dependent on external donor funding inmost settings, this restricts
treatment access and threatens the sustainability of programs.
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Background: Human Lymphatic Filariasis, caused by the nema-
tode parasites W. bancrofti and B. malayi infect about 128 million
people in 83 countries. Filarial Thioredoxin (TRX), amultifunctional
protein with antioxidant properties, plays an important role in
scavenging the hydroperoxides and protects parasites from host
immune system. The enzyme transglutaminase (TGA) catalyzes
post translational modiﬁcations of proteins, is required for growth
and development of the larval stages and has a role in in utero
development of microﬁlariae in adult female. Although TRX and
TGAhave been proved to be promising vaccine antigens in previous
studies they share ∼43-63% homology with host proteins which is
amajor drawback for vaccine development. Hence, an attemptwas
made to develop peptide vaccines using B and T epitopes from host
non-homologous regions of these keymetabolic enzymes. Epitope-
based vaccines have been extensively shown to be promising in
various diseases, capable of inducing protective immunity.
Methods & Materials: In this study, nematode speciﬁc regions
of TRX and TGA were screened and putative B/T cell epi-
topes in these host non-homologues regions were predicted by
immuno-informatic analysis. Four such peptides were chemically
synthesized and encapsulated in polymeric microspheres. The epi-
tope peptides were validated by various immunological assays
using mice models and human clinical samples. The epitopes were
then synthesized as di-peptide conjugates in different combina-
tions and tested for protective efﬁcacy against L3 larval challenge
in ﬁlarial experimental model.
Results: Two TRX peptides (TRXP1 and TRXP2) were found to
carry linear B cell epitopes while TGA carried a T cell epitope
(TGAP1) recognized both in mice and humans. The peptides were
synthesized as di-peptide conjugates in two different combina-
tions and the conjugateswere evaluated for their vaccine efﬁcacy in
Mastomys couchamodel. Thepeptide conjugates (PC2andPC3) con-
ferred high protection (71.97% and 72.73% respectively) which was
found to be signiﬁcantly greater (P <0.018) than the recombinant
proteins.
Conclusion: The study proves the potential of multi-epitope
vaccines for parasitic infections that exploits epitopes from mul-
tiple stages and/or multiple antigens.
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